- $910.44m
- $408.14m
- $24.05m
Acelyrin slides after reiterating merger with Alumis amid Concentra's buyout offer
Brief: Acelyrin Determines Unsolicited Indication Of Interest From Concentra Biosciences Not Reasonably Expected To Result In A Superior Proposal To Planned Alumis Merger
Brief: Acelyrin And Alumis Reaffirm Strategic And Financial Rationale Of Proposed Merger
Brief: Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger
Acelyrin jumps on Concentra Biosciences' buyout offer amid pending merger with Alumis
Acelyrin jumps on Concentra Biosciences' buyout offer amid pending merger with Alumis
Brief: ACELYRIN Confirms Receipt Of Unsolicited Indication Of Interest From Concentra Biosciences
Brief: Alumis And Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company
Brief: Alumis, Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company
Brief: Alumis Announces Positive Phase 1 Data For Cns Penetrant Tyk2 Inhibitor, A-005
Brief: Late-Breaking Data At EADV Of Esk-001 Demonstrate Significant Responses
Alumis resumes decline a day after first positive session post IPO
U.S. STOCKS ON THE MOVE-Tesla, Apple, AMD, Merck
Alumis dips day after listless Nasdaq debut
Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut (updated)
Alumis shares fall nearly 16% in Nasdaq debut
Therapy developer Alumis prices U.S. IPO at about $902 mln valuation (updated)
Therapy developer Alumis prices U.S. IPO at $16 per share
Brief: Alumis Says Pricing of Initial Public Offering Of 13.1 Mln Shares Of $16.00/SHR